Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Aurora, Colorado 80045


Purpose:

The purpose of the study is to study the safety of the combination of ranibizumab and MMC vs monotherapy MMC vs intravitreal ranibizumab injection in patients with glaucoma.


Study summary:

A common problem after undergoing trabeculectomy surgery to create a bleb (blister or bubble) to reduce intraocular pressure, is scarring of the opening. This scarring prevents fluid drainage and interferes with the proper functioning of the bleb. MMC (Mitomycin C) is usually administered intraoperatively, to reduce scarring and increase filtration. However, the failure rate of trabeculectomy remains high. Anti-VEGF agents have been used successfully in cases requiring bleb needling. The purpose of the study is to determine the safety of the combination of ranibizumab and MMC vs monotherapy MMC in patients with glaucoma. This is an open-label, Phase I/II safety study of 30 patients randomized to either treatment with ranibizumab 0.5 mg intravitreally injected (n=10), combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10) or MMC therapy alone (n=10). For the ranibizumab groups, a repeat injection of ranibizumab 0.5mg may be given PRN at 1 month if hypervascularity or neovascularization of the conjunctiva exists.


Criteria:

Inclusion Criteria: - glaucoma - undergoing trabeculectomy - 21 years of age or older Exclusion Criteria: - pregnancy or lactation - any condition the investigator believes would impose a significant hazard to the patient if investigational therapy were initiated - history of ocular surface disease - cataract surgery in the past 6 months - history of active inflammatory, infectious or idiopathic keratitis


NCT ID:

NCT00661583


Primary Contact:

Study Director
Malik Y. Kahook, MD
Rocky Mountain Lions Eye institute


Backup Contact:

N/A


Location Contact:

Aurora, Colorado 80045
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 20, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.